Adamantane-retropeptides, new building blocks for molecular channels
摘要:
Novel adamantane-oxalamide derivatives, N,N'-bis(1-adamantylglycine methyl ester)oxalamide (meso-1 and rac-1), N,N'-bis(3-aminoadamantane- 1-carboxylic acid methyl ester)oxalamide (2) and N,N'-bis(3-aminoadamantane-1-carboxylic acid)oxalamide (3) were prepared and structurally characterized by spectroscopic methods and X-ray analysis. Crystal packing of the structures meso-1 and rac-1 is defined by one-dimensional alpha-networks of hydrogen-bonded chains. The crystal structures of 2 and 3 are characterized by two-dimensional beta-networks of hydrogen bonds. The oxalamide 3 crystallizes as the solvates only. In the crystal structure of 3 the protic solvent participates in hydrogen bonding with the oxalamide moieties. However, in non-protic solvents 3 crystallizes as a solvate but the solvent does not participate in hydrogen bonding. The two-dimensional network of hydrogen bonds connecting molecules of 3 generates channels, which are filled by discrete solvent molecules. (C) 2007 Elsevier Ltd. All rights reserved.
Adamantane-retropeptides, new building blocks for molecular channels
摘要:
Novel adamantane-oxalamide derivatives, N,N'-bis(1-adamantylglycine methyl ester)oxalamide (meso-1 and rac-1), N,N'-bis(3-aminoadamantane- 1-carboxylic acid methyl ester)oxalamide (2) and N,N'-bis(3-aminoadamantane-1-carboxylic acid)oxalamide (3) were prepared and structurally characterized by spectroscopic methods and X-ray analysis. Crystal packing of the structures meso-1 and rac-1 is defined by one-dimensional alpha-networks of hydrogen-bonded chains. The crystal structures of 2 and 3 are characterized by two-dimensional beta-networks of hydrogen bonds. The oxalamide 3 crystallizes as the solvates only. In the crystal structure of 3 the protic solvent participates in hydrogen bonding with the oxalamide moieties. However, in non-protic solvents 3 crystallizes as a solvate but the solvent does not participate in hydrogen bonding. The two-dimensional network of hydrogen bonds connecting molecules of 3 generates channels, which are filled by discrete solvent molecules. (C) 2007 Elsevier Ltd. All rights reserved.
The present invention provides adamantyl-diamide derivatives of formula (1):
wherein R
1
and R
2
are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.
Antiproliferative and Antiviral Activity of Three Libraries of Adamantane Derivatives
作者:Nikola Basarić、Margareta Sohora、Nikola Cindro、Kata Mlinarić-Majerski、Erik De Clercq、Jan Balzarini
DOI:10.1002/ardp.201300345
日期:2014.5
Threelibraries of adamantanederivatives were synthesized and evaluated for antiviral and antiproliferativeactivities against a broad variety of DNA and RNA viruses. Whereas none of the compounds exhibit antiviralactivity at subtoxic concentrations, antiproliferativeactivity was found against murine leukemia cells (L1210), human T‐lymphocyte cells (CEM), and cervix carcinoma cells (HeLa) for 4
合成了三个金刚烷衍生物文库,并评估了针对多种 DNA 和 RNA 病毒的抗病毒和抗增殖活性。虽然这些化合物在亚毒浓度下均不表现出抗病毒活性,但在 4、8 和 10 年中发现对鼠白血病细胞 (L1210)、人 T 淋巴细胞 (CEM) 和宫颈癌细胞 (HeLa) 具有抗增殖活性。
Enantioselective Desymmetrization of 1,3‐Disubstituted Adamantane Derivatives via Rhodium‐Catalyzed C−H Bond Amination: Access to Optically Active Amino Acids Containing Adamantane Core
作者:Risa Yasue、Kazuhiro Yoshida
DOI:10.1002/adsc.202001419
日期:2021.3.16
85% ee (e.r.=92.4: 7.6) (>99% ee after recrystallization). The synthetic utility of the enantioenriched products as chiral building blocks was demonstrated by transforming one of them into a dipeptide derivative and a Schiff‐base ligand. The absolute configuration of one of the aminoacid derivatives was determined unambiguously by X‐ray single‐crystal structure analysis.
N-Adamantane-substituted tetrapeptide amides and the pharmacologically acceptable salts thereof are disclosed herein. These compounds are analogs of enkephalin wherein the methionine or leucine of position 5 has been substituted by an adamantyl amide and the glycine of position 2 has been substituted by various amino acid residues. Optionally the tyrosine of position 1 and the phenylalanine of position 4 may be substituted by various amino acid residues. These compounds exhibit agonist activity at opiate receptor sites and are useful as analgesics.
The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally substituted, methods for the production of the compounds based on the present invention, and methods for the coupling of the monomeric 3-aminoadamantane-1-carboxylic derivatives thus obtained to oligomers. The compounds based on the present invention are suitable for the utilisation as antiviral active ingredients, artificial ion channels, as well as for the therapy, diagnostics and prophylaxis of diseases in which a dysfunction of the GABA system occurs.